Compare Mesoblast Limited (MESO) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs PAGSEG Inc — how do they compare? Mesoblast Limited trades at $14.13 (market cap $1.75B), while PAGSEG Inc trades at $10.9 (market cap $2.94B). The key difference: PAGSEG Inc is the larger of the two by market cap, and PAGSEG Inc pays a 10.49% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and PAGSEG Inc for 26 Days on average.
| MESO | PAGS | |
|---|---|---|
Market Cap | $1.75B | $2.94B |
Volume | 239,027 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $20.96 | $12.00 |
52-Week Low | $13.19 | $8.44 |
Typical Hold Time | 14 Days | 26 Days |
Enterprise Value | $1.83B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
PAGS trades at $10.81, up 2.81% today, with a bullish technical signal from moving averages. The stock shows strong valuation metrics with a P/E of 7.1 and P/S of 0.74, supported by a 10.45% net income margin and recent earnings beats. A dividend of $0.28 is scheduled for September 2026, enhancing income appeal. Revenue growth remains steady, with 2026 guidance maintained despite a challenging macro environment.
Outlook is positive with analyst consensus at Buy (62.5%) and a $10.70 price target, though risks include elevated credit losses and Brazilian interest rate volatility. The stock's low valuation and dividend yield present a value opportunity, but investors must monitor execution on credit quality and banking growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
